<DOC>
	<DOCNO>NCT01412125</DOCNO>
	<brief_summary>Huntington 's disease ( HD ) rare , autosomal dominant , progressive neurodegenerative disorder typically become noticeable middle age . It clinically characterize progressive involuntary movement ( bradykinesia hyperkinesia ) , neuropsychiatric disturbance ( depression , irritability ) , cognitive impairment progress dementia . The striatum ( caudate putamen ) primary area neuronal degeneration HD . Today , validate curative treatment . HD affect approximately 6 000 patient France 30 000 individual consider risk disease . While disease gene discover capable predictive genetic diagnosis asymptomatic patient , clinical biological way predict age onset progressive profile patient . One fundamental characteristic disease extreme variability one patient term evolution onset action . Thus , inter-individual variability severely limit genetic counsel complicate neurological assessment . Increasingly , assume modifier gene may source inter-individual variability identification could help understand prediction disease progression . Given mutant protein ubiquitous , molecular dysfunction neuron could find peripheral cell bloodstream accessible investigation .</brief_summary>
	<brief_title>Study Biomarkers That Predict Evolution Huntington 's Disease</brief_title>
	<detailed_description>In context , propose focus research biological genetic marker also neuroimaging neuropsychological marker use paradigms time reaction measurement evoked potential . We hope identify sensitive marker degenerative process Huntington 's disease even patient carry gene may may report disease . The project center 2 ax : 1. identification genetic polymorphism may explain phenotypic variability see Huntington 's disease 2. identification biological , genetic imaging biomarkers could use predictor clinical progression Huntington 's disease This research base existence well follow well characterized cohort patient Francophone Huntington Network ( `` RESEAU HUNTINGTON de LANGUE FRANCAISE '' , RHLF ) . Therefore , help combine clinical biological expertise RHLF .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Inclusion Criteria ( patient ) : Voluntary patient symptomatic asymptomatic Patient number CAG â‰¥36 ) Patient know genetic status Age great 18 year equal 18 year Patient provide write informed consent Exclusion Criteria ( patient ) : Deterioration protocol prevent understand protocol Inclusion Criteria ( control ) : Voluntary control family history huntington 's disease Control number CAG &lt; 36 Age great 18 year equal 18 year Control provide write informed consent Exclusion Criteria ( control ) : Deterioration protocol prevent understanding protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Genetic polymorphism</keyword>
	<keyword>Neuroimaging marker</keyword>
	<keyword>Neuropsychology</keyword>
</DOC>